Cellular and Phenotypic Plasticity in Cancer

The process of Epithelial-Mesenchymal-Transition (EMT) is known to result in a phenotype change in cells from a proliferative state to a more invasive state. EMT has been reported to drive the metastatic spread of various cancers and has also been associated with drug resistance to cytotoxics and ta...

Full description

Saved in:
Bibliographic Details
Main Author: Petranel Theresa Ferrao (auth)
Other Authors: Andreas Behren (auth), Erik Thompson (auth), Robin Anderson (auth)
Format: Book Chapter
Published: Frontiers Media SA 2015
Subjects:
Online Access:Get Fullteks
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 03180naaaa2200385uu 4500
001 doab_20_500_12854_42865
005 20210211
020 |a 978-2-88919-662-3 
020 |a 9782889196623 
024 7 |a 10.3389/978-2-88919-662-3  |c doi 
041 0 |a English 
042 |a dc 
100 1 |a Petranel Theresa Ferrao  |4 auth 
700 1 |a Andreas Behren  |4 auth 
700 1 |a Erik Thompson  |4 auth 
700 1 |a Robin Anderson  |4 auth 
245 1 0 |a Cellular and Phenotypic Plasticity in Cancer 
260 |b Frontiers Media SA  |c 2015 
300 |a 1 electronic resource (77 p.) 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a The process of Epithelial-Mesenchymal-Transition (EMT) is known to result in a phenotype change in cells from a proliferative state to a more invasive state. EMT has been reported to drive the metastatic spread of various cancers and has also been associated with drug resistance to cytotoxics and targeted therapeutics. Recently phenotype switching akin to EMT has been reported in non-epithelial cancers such as metastatic melanoma. This process involves changes in EMT-Transcription Factors (EMT-TFs), suggesting that phenotype-switching may be common to several tumour types. It remains unclear as to whether the presence of both Epilthelial-like and Mesenchymal-like cells are a pre-requisite for phenotype switching within a tumour, how this heterogeneity is regulated, and if alteration of cell phenotype is sufficient to mediate migratory changes, or whether drivers of cell migration result in an associated phenotype switch in cancer cells. Similarly it has yet to be clarified if cells in an altered phenotype can be refractory to drug therapy or whether mediators of drug resistance induce a concurrent phenotypic change. Little is known today about the underlying genetic, epigenetic and transient changes that accompany this phenotypic switch and about the role for the tumor micro-environment in influencing it. Hence this is currently an area of speculation and keen interest in the Oncology field with wide-ranging translational implications. In this Frontiers Research Topic, we discuss our current understanding of these concepts in various cancer types including breast cancer, colorectal cancer and metastatic melanoma. This topic covers how these processes of cellular and phenotypic plasticity are regulated and how they relate to cancer initiation, progression, dormancy, metastases and response to cytotoxics or targeted therapies. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
653 |a crosstalk 
653 |a Immune System 
653 |a Phenotype-switching 
653 |a plasticity 
653 |a Exosomes 
653 |a EMT 
653 |a Therapy-resistance 
653 |a signalling 
653 |a heterogeneity 
653 |a Cancer 
856 4 0 |a www.oapen.org  |u http://journal.frontiersin.org/researchtopic/2968/cellular-and-phenotypic-plasticity-in-cancer  |7 0  |z Get Fullteks 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/42865  |7 0  |z DOAB: description of the publication